Fig. 3

Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice. Cangrelor was microinfused into bilateral DG regions of the hippocampus of mice for 21 days, followed by LPS (0.25 mg/kg, i.p.) or its vehicle was administered for 7 days, and then, the OFT, MWM, and NORT tests were conducted in mice. A Schematic representation of the drug treatment experiment design. B Representative immunoreactive bands of GPR17 protein in the hippocampus. GPR17 protein (C) and mRNA levels (D) in the hippocampus. β-Actin was used as an internal control, n = 4 mice/group. E Representative heat map of mouse movement in the OFT. F Total distance in the OFT was shown. G Representative trajectories of mice from each experimental group in the probe trial. H During the 2-day visible platform test, there were no differences in the escape latency among all groups. Escape latency was changed on the hidden platform during the 3-day acquisition trials. I The percentage of total time spent in the target quadrant during the probe trial. J Number of platform crossings during the probe trial test on day 6. K Average swimming speed among all groups in the 6 day tests. L Discrimination index was determined by performing the following calculation: (EB − EA)/(EB + EA). Values shown are expressed as mean ± SEM; n = 12 mice/group. *P < 0.05, ** P < 0.01 versus Veh + LPS